

Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/G4D73B6A7AADEN.html>

Date: May 2022

Pages: 41

Price: US\$ 3,500.00 (Single User License)

ID: G4D73B6A7AADEN

Abstracts

Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

According to the recently published report 'Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 - Drugs In Development, 2022'; Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) pipeline Target constitutes close to 6 molecules. Out of which approximately 6 molecules are developed by Companies.

Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) - Gamma-aminobutyric acid A receptor, alpha 3 or GABRA3 is a protein encoded by the GABRA3 gene. GABRA3 are ligand-gated chloride channels and are activated by the major inhibitory neurotransmitter in the mammalian brain and has been found to mediate anxiolytic activity, which plays a key role in emotional and behavioral control.

The report 'Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 - Drugs In Development, 2022' outlays comprehensive information on the Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3)

targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 1 and 1 respectively. Report covers products from therapy areas Central Nervous System, Dermatology and Genito Urinary System And Sex Hormones which include indications Anxiety Disorders, Epilepsy, Neuropathic Pain (Neuralgia), Depression, Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy), Fibromyalgia (Fibromyalgia Syndrome), Panic Disorders, Primary Hyperoxaluria, Primary Hyperoxaluria Type I, Primary Hyperoxaluria Type II and Pruritus.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3)

The report reviews Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) targeted therapeutics and enlists all their major and minor projects

The report assesses Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) development landscape

Develop and design in-licensing and out-licensing strategies by identifying

prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) - Overview

Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) - Companies Involved in Therapeutics Development

Baergic Bio Inc

Biocodex

Cerevel Therapeutics Holdings Inc

Engrail Therapeutics Inc

Saniona AB

Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) - Drug Profiles

BAER-101 - Drug Profile

Product Description

Mechanism Of Action

History of Events

darigabat - Drug Profile

Product Description

Mechanism Of Action

History of Events

NCT-10004 - Drug Profile

Product Description

Mechanism Of Action

History of Events

SAN-711 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Small Molecules to Agonize GABR for Neuropathic Pain and Fibromyalgia - Drug Profile

Product Description

Mechanism Of Action

History of Events

stiripentol - Drug Profile

Product Description

Mechanism Of Action

History of Events

Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) - Dormant Products

Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) - Discontinued Products

Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) - Product Development Milestones

Featured News & Press Releases

Mar 24, 2022: Saniona initiates positron emission tomography (PET) stage of SAN711 phase 1 clinical trial

Mar 24, 2022: Saniona initiates positron emission tomography (PET) stage of SAN711 phase 1 clinical trial

Feb 15, 2022: Cerevel Therapeutics announces positive topline results for Darigabat in phase 1 clinical trial in acute anxiety

Feb 10, 2022: Saniona initiates multiple ascending dose stage of SAN711 phase 1 clinical trial

Aug 31, 2021: BioStock: Saniona's clinical and regulatory progress during H1

Jun 30, 2021: Saniona initiates phase 1 clinical trial of SAN711

Jun 08, 2021: Saniona to present preclinical data on SAN711 at the 7th Congress of the European Academy of Neurology

Jan 28, 2021: Cerevel Therapeutics hosts Inaugural Virtual R&D event to review Darigabat (CVL-865) and provide overview of key preclinical programs

Oct 06, 2020: Cerevel Therapeutics announces first patient dosed in phase 2 trial of CVL-865, an investigational therapy in development for the treatment of Epilepsy

Dec 08, 2019: Cerevel Therapeutics announces phase 1 results for CVL-865, a Novel $\alpha 2/3/5$ -subtype GABAA Positive Allosteric Modulator in Development to treat Epilepsy

Nov 25, 2019: Cerevel Therapeutics to present safety, tolerability, and pharmacokinetics results from phase 1 trial of CVL-865

Apr 24, 2019: US Bioservices selected by Biocodex SAS to exclusively dispense

DIACOMIT (stiripentol)

Apr 09, 2019: Cerevel Therapeutics announces publication of phase 2a study results in Neurology on its most advanced investigational Epilepsy treatment

Feb 18, 2019: Sanionas SAN711 selected for clinical studies in itching and pain

Feb 13, 2019: NeuroCycle Therapeutics receives NIH SBIR Grant to study Dravet Syndrome drug candidate NCT10004

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Baergic Bio Inc, 2022

Pipeline by Biocodex, 2022

Pipeline by Cerevel Therapeutics Holdings Inc, 2022

Pipeline by Engrail Therapeutics Inc, 2022

Pipeline by Saniona AB, 2022

Dormant Projects, 2022

Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

I would like to order

Product name: Gamma-Aminobutyric Acid Receptor Subunit Alpha 3 (GABA(A) Receptor Subunit Alpha 3 or GABRA3) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/G4D73B6A7AADEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G4D73B6A7AADEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970